Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
; (12): 1193-1207, 2013.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-814839
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To conduct a meta-analysis to determine the efficacy of peginterferon alpha (PEG-IFN α) therapy versus IFN α, adefovir dipivoxil (ADV) and entecavir (ETV) for HBeAg-positive chronic hepatitis B patients in China.@*METHODS@#MEDLINE database and 3 main Chinese biomedical databases between 1966 and 2012 was retrieved. Two reviewers independently screened all reports to identify randomized controlled trials that evaluated PEG-IFN α therapy for the treatment of chronic hepatitis B in China.@*RESULTS@#Fourteen trials met the eligibility criteria for this Meta analysis. PEG-IFN α therapy was more effective than IFN α therapy in achieving ALT normalization, serum HBV DNA clearance, HBeAg seroconversion, serum HBeAg clearance and fibrosis improvement in Chinese hepatitis B patients (P<0.05). PEG-IFN α was obviously superior to ETV in HBeAg seroconversion and serum HBeAg clearance (P<0.05), but the seroconversion rate was low. The combination therapy of PEG-IFN α and ADV was more effective than ADV monotherapy in ALT normalization, serum HBV DNA clearance and HBeAg seroconversion (P<0.05). PEG-IFN α showed no priority to other treatment regimes in HBsAg clearance.@*CONCLUSION@#Treatment with PEG-IFN α is safe and effective, and can be prescribed as firstline treatment options for chronic hepatitis B patients in China. Data are too limited to exclude a substantial benefit or harm of PEG-IFN α combination therapy for CHB patients in China.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Polyethylene Glycols
/
Adenine
/
China
/
Interferon-alpha
/
Hepatitis B, Chronic
/
Therapeutic Uses
/
Drug Therapy
/
Drug Therapy, Combination
/
Organophosphonates
Type of study:
Controlled clinical trial
/
Prognostic study
/
Systematic review
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Central South University(Medical Sciences)
Year:
2013
Document type:
Article